Entry id

1_mblwokvh

For women at high risk of recurrence from their HR positive, HER2 negative breast cancer, I think, it is very important for them to have a quantitative understanding of what their risk of recurrence is over the first 5 years and over their lifetime. And then we want to offer them, of course, every proven treatment to decrease that risk of recurrence. I think it is very important to frame this initially, when you are first meeting a patient, and walk through what the treatment plan will be, giving them a quantitative understanding of exactly how much benefit – what is the reduction risk of recurrence they get? – every step along the way. And women really want to get as low on the risk of recurrence as possible, of course. If you meet a patient who is midstream in her therapy, again, you can say, well, you had this treatment here, this is my estimation of what your residual risk of recurrence is, and here is what I recommend. Let’s go through this step-by-step processing what we can do given the proven clinical trial data to reduce your risk of recurrence. And I write it down, and I think it is very helpful to be as quantitative as possible in telling that story.